Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Hiddemann, Wolfgang  [Clear All Filters]
2015
Vick B, Rothenberg M, Sandhöfer N, Carlet M, Finkenzeller C, Krupka C, Grunert M, Trumpp A, Corbacioglu S, Ebinger M, et al. An Advanced Preclinical Mouse Model for Acute Myeloid Leukemia Using Patients' Cells of Various Genetic Subgroups and In Vivo Bioluminescence Imaging. PLoS One. 2015;10(3):e0120925.
2016
Hubmann M, Fritsch S, Zoellner A-K, Prevalsek D, Engel N, Bücklein V, Mumm F, Schulz C, Stemmler HJoachim, Jäger G, et al. Occurrence, risk factors and outcome of adenovirus infection in adult recipients of allogeneic hematopoietic stem cell transplantation. J Clin Virol. 2016;82:33-40.
Pohlen M, Thoennissen NH, Braess J, Thudium J, Schmid C, Kochanek M, Kreuzer K-A, Lebiedz P, Görlich D, Gerth HU, et al. Patients with Acute Myeloid Leukemia Admitted to Intensive Care Units: Outcome Analysis and Risk Prediction. PLoS One. 2016;11(8):e0160871.
2018
Heckl BChristine, Carlet M, Vick B, Roolf C, Alsadeq A, Grunert M, Liu W-H, Liebl A, Hiddemann W, Marschalek R, et al. Frequent and reliable engraftment of certain adult primary acute lymphoblastic leukemias in mice. Leuk Lymphoma. 2018:1-4.
2019
Sandner A-S, Weggel R, Mehraein Y, Schneider S, Hiddemann W, Spiekermann K. Frequency of hematologic and solid malignancies in the family history of 50 patients with acute myeloid leukemia - a single center analysis. PLoS One. 2019;14(4):e0215453.
2020
Bamopoulos SA, Batcha AMN, Jurinovic V, Rothenberg-Thurley M, Janke H, Ksienzyk B, Philippou-Massier J, Graf A, Krebs S, Blum H, et al. Clinical presentation and differential splicing of SRSF2, U2AF1 and SF3B1 mutations in patients with acute myeloid leukemia. Leukemia. 2020.
Alig S, Jurinovic V, Esfahani MShahrokh, Haebe S, Passerini V, Hellmuth JC, Gaitzsch E, Keay W, Tahiri N, Zoellner A, et al. Evaluating upfront high-dose consolidation after R-CHOP for follicular lymphoma by clinical and genetic risk models. Blood Adv. 2020;4(18):4451-4462.
2021
Moser C, Jurinovic V, Sagebiel-Kohler S, Ksienzyk B, Batcha AMN, Dufour A, Schneider S, Rothenberg-Thurley M, Sauerland CM, Görlich D, et al. A Clinically Applicable Gene Expression based Score predicts Resistance to Induction Treatment in Acute Myeloid Leukemia. Blood Adv. 2021.
Zoellner A-K, Unterhalt M, Stilgenbauer S, Hübel K, Thieblemont C, Metzner B, Topp M, Truemper L, Schmidt C, Bouabdallah K, et al. Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial. Lancet Haematol. 2021;8(9):e648-e657.
2022
Alcazer V, Bonaventura P, Tonon L, Michel E, Mutez V, Fabres C, Chuvin N, Boulos R, Estornes Y, Maguer-Satta V, et al. HERVs characterize normal and leukemia stem cells and represent a source of shared epitopes for cancer immunotherapy. Am J Hematol. 2022.
Hermine O, Jiang L, Walewski J, Bosly A, Thieblemont C, Szymczyk M, Pott C, Salles G, Feugier P, Hübel K, et al. High-Dose Cytarabine and Autologous Stem-Cell Transplantation in Mantle Cell Lymphoma: Long-Term Follow-Up of the Randomized Mantle Cell Lymphoma Younger Trial of the European Mantle Cell Lymphoma Network. J Clin Oncol. 2022:JCO2201780.
2023
Fischer L, Jiang L, Bittenbring JThomas, Huebel K, Schmidt C, Duell J, Metzner B, Krauter J, Glass B, Huettmann A, et al. The addition of rituximab to chemotherapy improves overall survival in mantle cell lymphoma-a pooled trials analysis. Ann Hematol. 2023.
Niederwieser D, Lang T, Krahl R, Heinicke T, Maschmeyer G, Al-Ali HKathrin, Schwind S, Jentzsch M, Cross M, Kahl C, et al. Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study. Ann Hematol. 2023.
Eckardt J-N, Röllig C, Metzeler K, Heisig P, Stasik S, Georgi J-A, Kroschinsky F, Stölzel F, Platzbecker U, Spiekermann K, et al. Unsupervised meta-clustering identifies risk clusters in acute myeloid leukemia based on clinical and genetic profiles. Commun Med (Lond). 2023;3(1):68.
2024
Scheubeck G, Hoffmann M, Jurinovic V, Fischer L, Unterhalt M, Schmidt C, Böck H-P, Dührsen U, Kaesberger J, Kremers S, et al. Rituximab, gemcitabine and oxaliplatin in relapsed or refractory indolent and mantle cell lymphoma: results of a multicenter phase I/II-study of the German Low Grade Lymphoma Study Group. Ann Hematol. 2024.